FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. The Company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor biology to generate clinical programs targeting multiple therapeutic areas. FibroGen's most advanced product candidate, roxadustat, is an oral small molecule inhibitor of HIF prolyl hydroxylases in Phase 3 clinical development for the treatment of anemia in chronic kidney disease.

FibroGen's second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.

Company Growth (employees)
San Francisco, US
Size (employees)
364 (est)
FibroGen was founded in 1993 and is headquartered in San Francisco, US

FibroGen Office Locations

FibroGen has an office in San Francisco
San Francisco, US (HQ)
409 Illinois St

FibroGen Financials and Metrics

FibroGen Financials

FibroGen's revenue was reported to be $179.6 m in FY, 2016

Revenue (Q2, 2017)

29 m

Net income (Q2, 2017)

(33.2 m)

EBIT (Q2, 2017)

(31.4 m)

Market capitalization (13-Dec-2017)

3.4 b

Cash (30-Jun-2017)

290.3 m
FibroGen's current market capitalization is $3.4 b.
USDFY, 2015FY, 2016


180.8 m179.6 m

Revenue growth, %


R&D expense

214.1 m187.2 m

General and administrative expense

44.4 m46 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


16.3 m120.6 m19.5 m28.3 m89.3 m30.1 m26.9 m29 m

R&D expense

50.5 m51.6 m52.1 m43.7 m52.4 m40.6 m46.7 m47 m

General and administrative expense

10.5 m9.7 m11.2 m11.4 m10.4 m11.6 m11.5 m13.4 m

Operating expense total

61 m61.2 m63.3 m55.1 m62.8 m52.2 m58.3 m60.4 m
USDFY, 2015FY, 2016


153.3 m173.8 m

Accounts Receivable

15.4 m10.4 m


4 m2.9 m

Current Assets

200.6 m266.5 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


128.4 m236.5 m208.7 m141 m190.4 m198.3 m170.6 m290.3 m

Accounts Receivable

7 m12.2 m7.4 m5.9 m18.1 m7.7 m7.2 m8.9 m

Current Assets

155.4 m263.6 m232.6 m184 m252.3 m253.5 m256.6 m371.3 m


131.7 m130.5 m129.6 m127.6 m126.3 m124.8 m122.8 m122.6 m
USDFY, 2015FY, 2016

Net Income

(85.8 m)(61.7 m)

Depreciation and Amortization

5.7 m6 m

Accounts Receivable

(2 m)5 m


978 k1.1 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(46.4 m)10.7 m(34.4 m)(27.8 m)(3.5 m)(27.7 m)(33.2 m)(66.3 m)

Depreciation and Amortization

2.8 m4.2 m1.5 m3 m4.5 m1.5 m3.1 m

Accounts Receivable

7 m1.3 m6.1 m9.5 m(2.7 m)7.7 m3.2 m1.5 m

Accounts Payable

2.4 m(636 k)(317 k)(5 m)(3 m)(4.5 m)(3.3 m)(3 m)
Y, 2017

Financial Leverage

2.4 x
Show all financial metrics

FibroGen Operating Metrics

FY, 2016

Phase III Trials


Phase II Trials




Patent Portfolios

Show all operating metrics

FibroGen Market Value History

FibroGen Revenue Breakdown

FibroGen's Web-traffic and Trends

FibroGen Online and Social Media Presence

FibroGen News and Updates

Global Chronic Kidney Disease (CKD) Drugs arket 2017 Share, Trend, Segmentation and Forecast to 2023

Global Chronic Kidney Disease (CKD) Drugs market is expected to grow from $12.87 billion in 2016 to reach $16.13 billion by 2023 with a CAGR of 3.2% Posted via Industry Today. Follow us on Twitter @IndustryToday

FibroGen Company Life and Culture

You may also be interested in